← Back to Search

Monoclonal Antibodies

Cryo-activation for Non-Small Cell Lung Cancer

N/A

Waitlist Available

Led By Moishe Liberman, MD PhD

Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up every 8 weeks (until disease progression or for a maximum pembrolizumab treatment duration of 2 years), every 3 months thereafter (for up to a total of 5 years)

Awards & highlights

Study Summary

This trial is testing whether adding cryo-activation to ICB in advanced NSCLC will help the ICB work better.

Eligible Conditions

Non-small Cell Lung Cancer Metastatic
Cryotherapy Effect

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ every 8 weeks (until disease progression or for a maximum pembrolizumab treatment duration of 2 years), every 3 months thereafter (for up to a total of 5 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~every 8 weeks (until disease progression or for a maximum pembrolizumab treatment duration of 2 years), every 3 months thereafter (for up to a total of 5 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and every 8 weeks (until disease progression or for a maximum pembrolizumab treatment duration of 2 years), every 3 months thereafter (for up to a total of 5 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Best overall response rate (BORR; change from baseline)

Secondary outcome measures

Incidence of treatment-related adverse events (Safety and tolerability)

Overall survival (OS)

Progression-free survival (PFS)

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Malnutrition, Hypercalcemia and Weakness

Pneumothorax

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

Trial Design

1Treatment groups

Experimental Treatment

Group I: Cryo-activation and anti-PD-1 monotherapy combinationExperimental Treatment2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cryo-activation

2021

N/A

~20

Pembrolizumab

2017

Completed Phase 2

~2010

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor

366 Previous Clinical Trials

129,622 Total Patients Enrolled

Moishe Liberman, MD PhDPrincipal InvestigatorCHUM

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Have any other clinical trials employed Cryo-activation as a treatment?

"Currently, there are 960 studies researching Cryo-activation with 122 of those in their third phase. Most of these studies take place in Houston, Texas; however, 35938 locations across the world have conducted research for this treatment."

Answered by AI

Does this research endeavor require any more participants?

"According to clinicaltrials.gov, recruitment is still open for this medical trial which was first launched on May 1st 2021 and recently updated on June 22nd 2022."

Answered by AI

How many participants can participate in this trial at one time?

"Affirmative. Clinicaltrials.gov confirms that this clinical investigation, which was first advertised on May 1st 2021, is actively seeking candidates for enrollment. 15 volunteers are being sought from a single medical centre."

Answered by AI

What purpose does the practice of Cryo-activation typically serve?

"Cryo-activation is employed in the treatment of malignant neoplasms and can be utilized to treat a variety of ailments, including unresectable melanoma, microsatellite instability high, and cases where chemotherapy has not sufficiently reduced tumor progression."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)

2021. "Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04793815.